Literature DB >> 31134297

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Katie M Leick1,2,3, Joel Pinczewski1,4, Ileana S Mauldin1,3, Samuel J Young3,5, Donna H Deacon1,3, Amber N Woods3,6, Marcus W Bosenberg7, Victor H Engelhard3,6, Craig L Slingluff8,9.   

Abstract

Immune-cell infiltration is associated with improved survival in melanoma. Human melanoma metastases may be grouped into immunotypes representing patterns of immune-cell infiltration: A (sparse), B (perivascular cuffing), and C (diffuse). Immunotypes have not been defined for murine melanomas, but may provide opportunities to understand mechanism-driving immunotype differences. We performed immunohistochemistry with immune-cell enumeration, immunotyping, and vascular density scoring in genetically engineered (Braf/Pten and Braf/Pten/β-catenin) and transplantable (B16-F1, B16-OVA, and B16-AAD) murine melanomas. The transplantable tumors were grown in subcutaneous (s.c.) or intraperitoneal (i.p.) locations. Braf/Pten and Braf/Pten/β-catenin tumors had low immune-cell densities, defining them as Immunotype A, as did B16-F1 tumors. B16-OVA (s.c. and i.p.) and B16-AAD s.c. tumors were Immunotype B, while B16-AAD i.p. tumors were primarily Immunotype C. Interestingly, the i.p. location was characterized by higher immune-cell counts in B16-OVA tumors, with counts that trended higher for B16-F1 and B16-AAD. The i.p. location was also characterized by higher vascularity in B16-F1 and B16-AAD tumors. These findings demonstrate that spontaneously mutated neoantigens in B16 melanomas were insufficient to induce robust intratumoral immune-cell infiltrates, but instead were Immunotype A tumors. The addition of model neoantigens (OVA or AAD) to B16 enhanced infiltration, but this most often resulted in Immunotype B. We find that tumor location may be an important element in enabling Immunotype C tumors. In aggregate, these data suggest important roles both for the antigen type and for the tumor location in defining immunotypes.

Entities:  

Keywords:  B16 melanoma; Immune-cell density; Immunotype; Vascular density

Mesh:

Substances:

Year:  2019        PMID: 31134297      PMCID: PMC6887106          DOI: 10.1007/s00262-019-02345-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  44 in total

Review 1.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

3.  Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Authors:  Eleanor Clancy-Thompson; Thomas J Perekslis; Walburga Croteau; Matthew P Alexander; Tamer B Chabanet; Mary Jo Turk; Yina H Huang; David W Mullins
Journal:  Cancer Immunol Res       Date:  2015-06-05       Impact factor: 11.151

4.  Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules.

Authors:  M H Newberg; D H Smith; S B Haertel; D R Vining; E Lacy; V H Engelhard
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

5.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Authors:  Mahesh Yadav; Suchit Jhunjhunwala; Qui T Phung; Patrick Lupardus; Joshua Tanguay; Stephanie Bumbaca; Christian Franci; Tommy K Cheung; Jens Fritsche; Toni Weinschenk; Zora Modrusan; Ira Mellman; Jennie R Lill; Lélia Delamarre
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

7.  Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Authors:  Stefani Spranger; Jason J Luke; Riyue Bao; Yuanyuan Zha; Kyle M Hernandez; Yan Li; Alexander P Gajewski; Jorge Andrade; Thomas F Gajewski
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

8.  Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Authors:  Yared Hailemichael; Amber Woods; Tihui Fu; Qiuming He; Michael C Nielsen; Farah Hasan; Jason Roszik; Zhilan Xiao; Christina Vianden; Hiep Khong; Manisha Singh; Meenu Sharma; Faisal Faak; Derek Moore; Zhimin Dai; Scott M Anthony; Kimberly S Schluns; Padmanee Sharma; Victor H Engelhard; Willem W Overwijk
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

9.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response.

Authors:  M C Mihm; C G Clemente; N Cascinelli
Journal:  Lab Invest       Date:  1996-01       Impact factor: 5.662

10.  Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity.

Authors:  J David Peske; Elizabeth D Thompson; Lelisa Gemta; Richard A Baylis; Yang-Xin Fu; Victor H Engelhard
Journal:  Nat Commun       Date:  2015-05-13       Impact factor: 14.919

View more
  6 in total

1.  The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

Authors:  Katie M Leick; Anthony B Rodriguez; Marit M Melssen; Mouadh Benamar; Robin S Lindsay; Rebeka Eki; Kang-Ping Du; Mahmut Parlak; Tarek Abbas; Victor H Engelhard; Craig L Slingluff
Journal:  Ann Surg       Date:  2019-10       Impact factor: 12.969

2.  Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes.

Authors:  Max O Meneveau; Zeyad T Sahli; Kevin T Lynch; Ileana S Mauldin; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

3.  Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates.

Authors:  Minyoung Kwak; Gulsun Erdag; Katie M Leick; Stefan Bekiranov; Victor H Engelhard; Craig L Slingluff
Journal:  J Transl Med       Date:  2021-08-28       Impact factor: 8.440

4.  Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.

Authors:  Lien De Beck; Robin Maximilian Awad; Veronica Basso; Noelia Casares; Kirsten De Ridder; Yannick De Vlaeminck; Alessandra Gnata; Cleo Goyvaerts; Quentin Lecocq; Edurne San José-Enériz; Stefaan Verhulst; Ken Maes; Karin Vanderkerken; Xabier Agirre; Felipe Prosper; Juan José Lasarte; Anna Mondino; Karine Breckpot
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

5.  Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment.

Authors:  Fangfang Lv; Huifang Liu; Gaoqian Zhao; Erman Zhao; Hongyu Yan; Ruijun Che; Xinjian Yang; Xiaohan Zhou; Jinchao Zhang; Xing-Jie Liang; Zhenhua Li
Journal:  iScience       Date:  2021-12-18

6.  Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy.

Authors:  Anirban Banerjee; Dongge Li; Yizhan Guo; Bayan Mahgoub; Lea Paragas; Jacqueline Slobin; Zhongcheng Mei; Amir Manafi; Atsushi Hata; Kang Li; Lei Shi; John Westwick; Craig Slingluff; Eric Lazear; Alexander Sasha Krupnick
Journal:  J Immunol       Date:  2021-06-21       Impact factor: 5.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.